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mean estimates in QALYs in favour of vinflumine can be quite different depending 
on how censored patients are handled especially when proportion of censoring 
differs by treatment group.
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Objectives: The present study used long-term EQ-5D scores to evaluate patients 
with metastatic breast cancer (MBC) in a randomized control trial (RCT). MethOds: 
Patients with HER2-negative MBC were randomly allocated to the S-1 (an oral fluo-
ropyrimidine) or taxane (paclitaxel or docetaxel) group. The primary endpoint was 
overall survival (OS), and QOL was a secondary endpoint. EQ-5D scores were sur-
veyed at pre-treatment, three months after randomization, and every six months 
thereafter. Mean scores were assessed by repeated measured ANOVA including 
baseline, group, time and interaction of group and time. Minimal important dif-
ference (MID) analysis was also performed by defining the MID of EQ-5D as 0.05 
or 0.1. When MID analysis was applied to the score during fist-line therapy, pro-
gression was treated as a competing risk. Results: A total of 618 patients with 
MBC were randomly allocated to both groups (N= 309 each). S-1 was non-inferior to 
taxanes for OS (median OS: S-1, 35.0 months; taxanes, 37.2 months). The number 
of patients in the EQ-5D population was 208 and 175 in S-1 and taxane groups, 
respectively. Mean duration of the EQ-5D response was 21 months for both groups. 
Mean EQ-5D scores up to 60 months were 0.748 and 0.741 in S1 and taxane groups, 
respectively. No significant difference was observed by ANOVA or MID analysis. 
During first-line therapy, mean EQ-5D score was 0.810 and 0.781 in S-1 and taxane 
groups up to 36 months, although in the post-progression period, scores decreased 
to 0.729 and 0.703, respectively. Gray’s test revealed that S-1 significantly delayed 
the decrease in QOL score. The size of the MID (0.05 or 0.1) did not influence the 
results. cOnclusiOns: This study analyzed long-term EQ-5D scores of patients 
with MBC from RCT data. The QOL score of S-1 was higher during first-line therapy.
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Objectives: Discrete choice experiments (DCE) are an important method for 
capturing data on the patient preferences. Neuroendocrine tumors (NET) are a rare 
disease and therefore a sufficient number of study participants for preference 
studies is difficult to recruit. Moreover there is hardly any international stand-
ard for the determination of the appropriate number of study participants in 
DCEs. Amongst others, suggestions on sample size have been made by Orme 
and Louviere. MethOds: Patient-relevant outcomes concerning alternative 
treatment options of NET were weighted using a DCE including six attributes. 
Akaike information criterion (AIC), and Bayesian information criterion (BIC) 
together with the standard error (SE) were used to check the model fit and to 
determine the most appropriate sample size. For the sensitivity analysis dif-
ferent participants were randomly drawn from the study sample. Results: 
N= 275 NET-patients (48.5% male, mean age 58.4 years) could be included. With 
the maximum number of included participants all six attributes resulted in sig-
nificant values (p< 0.05). This sample sizes then accounts for an AIC= 3901.391, 
BIC= 4043.999 and a mean standard error (SE) of 0.057. Within the analysis an 
increasing sample size linearly improves the model fit. When including N= 30 
the mean SE does not fit the given 0.05 level (0.173). This improves with a higher 
sample size. Consequently, including N= 90 results in a mean SE below 0.1 with 
BIC= 4043.999 and AIC= 3901.391. The mean SE falls to 0.065 when including N= 210 
(BIC= 3169.285; AIC= 3032.256) cOnclusiOns: Using the sensitivity analysis it can 
be shown that the model fit improves proportionally. An optimal sample size could 
therefore be approximated. Based on the preliminary results it is evident that with 
the given design and the given number of attributes and level a total N of at least 
275 participants is appropriate to conduct a DCE.
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Objectives: Neuroendocrine tumors (NET) are relatively rare, usually slow-growing 
malignant tumors. So far there are no data on the patient preferences regarding the 
therapy of NET. This empirical study aimed at the elicitation of patient preferences 
in the drug treatment of NET. MethOds: Based on qualitative patient interviews 
and an AHP, patient-relevant outcomes were analyzed and weighted using a discrete 
choice experiment (DCE). Six patient-relevant attributes were included. Patients 
were recruited with the help of a NET support group. For the DCE an experimental 
design (3*3 + 3*6 Design) was created using Ngene. The selected design consisted of 
84 choices, which were divided into 7 blocks. Participants were randomly assigned to 
these blocks. The analysis of DCE included random parameter logit models, condi-
tional logit models, and latent class models. Results: N = 275 NET-patients (51.6% 
female, mean age 58.4 years) participated. Under the chosen decision model the 
preference analysis within the random parameter logit model, taking into account 
Guidelines. Mode equivalence between paper and electronic versions of the EORTC 
Quality of Life Questionnaire (EORTC QLQ-C30;v3.0) and its Breast Cancer Module 
(QLQ-BR23;v1.0) was evaluated, as well as their usability on two electronic devices 
with different screen sizes. MethOds: Adult women with metastatic breast cancer 
(mBC) who had not received chemotherapy for metastatic disease were screened. 
Using an alternating crossover study design, half completed questionnaires on paper 
first, followed by a tablet (10.1″screen) and a handheld (4.5″screen); the other half 
used the handheld first, followed by tablet and paper. To optimize recall, the think-
aloud method was used and cognitive debriefing interviews were conducted after 
each questionnaire was completed on each device. Usability questions were asked 
after completion of both questionnaires on a device. Results: 10 mBC patients 
were interviewed. Most patients reported that their answers would not differ on 
paper vs devices (tablet:C30= 70%;BR23= 100%), (handheld:C30= 90%;BR23= 90%). 
No participants attributed potential differences to interpreting items differently 
on the different modalities. 100% easily accessed questionnaires on the devices, 
understood instructions and easily moved from question-to-question. 90% were 
satisfied with the touchscreens, and all noted they could use either device inde-
pendently. Patients preferred the tablet vs handheld due to its larger screen; yet 
all preferred the handheld’s one-question-per-screen presentation, which allowed 
for greater focus. All patients indicated that screen size did not influence usability 
and that either device was acceptable to complete questionnaires. cOnclusiOns: 
This study demonstrated mode equivalence between paper and electronic versions 
of EORTC-C30 and BR23, as well as between two devices. The devices were equally 
acceptable, providing evidence for their usability to collect PRO information from 
similar patients in clinical trials.
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Objectives: Nonadherence to hormonal therapy is known to impact health out-
comes in patients with breast cancer. We measured nonadherence to aromatase 
inhibitors using a novel, clinic-based patient-reporting system. MethOds: Patients 
of The West Cancer Center (Memphis, TN) were surveyed in the clinic prior to a 
scheduled appointment using the Patient Care Monitor system, a tablet-based, 
patient-reported outcomes platform. Adults diagnosed with breast cancer and 
prescribed an aromatase inhibitor were eligible to participate. The survey included 
30 questions and used three established instruments, including the Morisky 
Medication Adherence Scale and Medication Adherence Reasons Scale. The survey 
polled patients on their adherence to aromatase inhibitors, reasons for nonadher-
ence, and health literacy. Results: Over the course of 45 days, 3016 patients were 
self-screened for eligibility and interest; 1105 indicated interest; and 110 patients 
were fully eligible and completed the survey. Respondents were well-distributed 
by medication: anastrazole (42.2%), exemestane (33.9%), and letrozole (23.9%). 
Most patients (82.6%) reported being fully adherent (missed 0 days) in the past 
week; however, only 67.9% reported high adherence (score = 4) according to the 
Morisky Medication Adherence Scale (Spearman rho= -0.457, p-value< 0.0001). 
Mean adherence values or days missed did not differ significantly by medication 
or health literacy level. Among patients who reported missing at least one day in 
the previous week, the most often cited reasons were: simply missing the dose 
(44.4%), having problems forgetting things (38.9%), and concerns about side effects 
(33.3%). cOnclusiOns: Adherence to hormonal therapy remains suboptimal and 
determining reasons for nonadherence prior to scheduled visits may assist provid-
ers in guiding patients. Moreover, the clinic’s Patient Care Monitor system is a novel 
patient engagement platform to collect patient-reported adherence data outside 
of the medical encounter, and may be leveraged to provide adherence and toxicity 
information to the healthcare team in real time.
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Objectives: Utility analyses have previously been conducted for the Phase III 
trial of vinflunine (VFL) versus best supportive care (BSC) for the treatment of 
advanced or metastatic transitional cell carcinoma of the urothelial tract (TCCU). 
Results were presented according to progression status. The present study aims 
to calculate quality-adjusted life years (QALYs) for each patient and summarise 
results by treatment group. MethOds: QALYs were calculated by patient using 
the area under the curve technique. Assumptions included that changes between 
utility measures over time were linear and utility at the time of death is zero. 
Once QALYs were calculated for all patients, univariate summaries were produced 
for both treatments separately considering different scenarios based on when 
baseline was recorded and how censored patients are handled in the QALY cal-
culation. The mean differences between treatments were evaluated using p-value 
derived from a two sample t-test and non-parametric Wilcoxon rank sum test. 
An analysis of covariance (ANCOVA), adjusting for baseline utility, was also per-
formed. Results: A total of 242 patients from the VFL and 103 from the BSC group 
had utility data and were eligible for the study. All BSC patients were observed to 
die, whilst 6% of VFL patients were censored and required imputation of death 
for QALY calculation. The estimated mean difference in QALY between treatment 
groups always favoured vinflunine regardless of method of analysis. Point esti-
mate ranged between -0.152 to -0.061. ANCOVA analyses move the point estimate 
slightly more in favour of vinflunine compared with unadjusted analyses. This 
was expected as the baseline utility was higher in the BSC group (0.781) compared 
to vinflunine (0.766). cOnclusiOns: Sensitivity analyses show that difference 
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sive disease), response (with/without complete response), and adverse events (with/
without grade ≥ 3 AEs). Generalized estimating equation (GEE) models provided 
direct estimation of HSUVs, controlling for confounders. Mapped HSUVs were com-
pared with published HSUVs in RRMM to assess reliability. Results: The algorithm 
that included the EORTC QLQ-C30 and EORTC QLQ-MY20 produced reliable HSUV 
estimates providing greater differentiation between health states. The overall mean 
estimate for progression-free disease (PFD) was 0.733. PFD with response was 0.744 
and PFD with no response was 0.704. The difference between scores with/without 
grade 3 AEs suggested a utility loss of 0.029; the AE decrement was greater (0.034) 
when using a proxy measure of patients who were off treatment but not in pro-
gressive disease. Similar patterns across the health states were seen by treatment 
regimen throughout the duration of the trial. GEE results were consistent with 
descriptive summaries. cOnclusiOns: Mapped EQ-5D scores showed a consistent 
trend across health states, with higher HSUVs for pre-progression than progressive 
disease, for response versus no response, and without AEs versus with AEs. HSUVs 
were dependent on disease state and treatment regimen. The algorithm including 
both the EORTC QLQ-C30 and EORTC QLQ-MY20 provided reliable HSUV estimates 
in this RRMM population.
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Objectives: Mapping a disease specific measure of quality of life to a generic 
instrument is one available technique to obtain utility values for cost-effectiveness 
studies. Based on a literature review on mapping techniques in oncology, we found 
that three models performed best: an OLS (Ordinary Least Square) regression 
with spline transformation, a multinomial logistic regression and a beta binomial 
regression. Our objective was to compare those three methods and a standard 
OLS regression for the mapping of the EORTC QLQ-C30 questionnaire to EQ-5D 
in patients with non-small cell lung cancer (NSCLC). MethOds: We used data 
from a cross-sectional study performed in a Canadian cancer centre where QLQ-
C30 and EQ-5D questionnaires were completed on a single visit by 172 patients. 
We compared the results obtained with the OLS regression and the other meth-
ods according to the goodness-of-fit of the model (adjusted-R2) and the predic-
tive ability (Mean Absolute Deviation or MAE and the Root Mean Square Error or 
RMSE). Analyses were replicated for 3 utility tariffs (US, UK and France). Results: 
We found a mean observed utility of 0.6768 in our sample (standard deviation = 
0.2848). The OLS regression with spline dominated all other methods, whichever 
tariff was used. With the UK tariff, the adjusted R2, MAE and RMSE were 0.6507, 
0.1120 and 0.1683 respectively for the OLS with spline, vs. 0.5796, 0.1301 and 0.1847 
respectively for the standard OLS. Better goodness-of-fit and predictive ability 
were obtained with the US tariff (adjusted R2 of 0.6900, MAE of 0.0694 and RMSE 
of 0.1114 for OLS with splne). cOnclusiOns: Using OLS with spline provides a 
notable improvement in goodness-of-fit and a better predictive ability compared 
to other regressions. Further analysis will be performed to observe the robustness 
of those results on other datasets.
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Objectives: This systematic literature review (SLR) aimed to identify health 
related quality of life (HRQoL) and health utility parameters among newly diag-
nosed multiple myeloma (MM) patients. MethOds: Systematic searches were 
conducted in literature databases including Embase® and MEDLINE® from Januray 
2005 to June 2015. English language studies, regardless of design and interven-
tion were included. Each study was reviewed by two independent reviewers; any 
disagreements were resolved by a third reviewer. Results: Out of the 680 cita-
tions retrieved from literature databases, 12 were included in the review. The 
included studies were observational (n= 6), randomised controlled trials (n= 5), or 
cost-effectiveness analysis (n= 1). Of 12 included studies, seven were conducted in 
US, three in Europe, and one each in Europe/US and Europe/other countries. Most 
commonly reported HRQoL scales were EORTC OLQ-C30, QLQ-MY20, and FACT-MM; 
while, health utility was estimted by EQ-5D. The HRQoL was significantly impaired 
in patients with MM compared to normative patients in terms of EORTC QLQ-C30 
(p< 0.01); with QoL, dyspnoea, physical functioning, role functioning, and social 
functoning subscales being the most affected. Further, disease progression was 
associated with a worsening in HRQOL scores (p< 0.001). Impaired HRQoL was 
reported in patients with MM because of disease related symptoms like bone pain 
and fatigue. Mean pain scores worsened with more severe disease stage (p< 0.05). 
Impaired HRQoL due to higher fatigue and pain scores was associated with shorter 
overall survival. Males had better HRQoL scores compared to females (p= 0.04) and 
blacks had better HRQoL scores compared to non-blacks (p= 0.03). Additionally, 
impaired health-related utility values were reported in patients with MM as sug-
ested by a mean EQ-5D score of less than 0.5. cOnclusiOns: Disease severity, 
gender, and race are few of the parameters that are associated with deterioration 
of HRQoL in patients with newly-diagnosed MM. Delaying disease progression 
could possibly help to improve HRQoL.
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the 95% confidence interval, showed a predominance for the attribute “overall sur-
vival” (coef: 1,568). The attributes “response to treatment” (coef: 0,617) and “stabi-
lization of tumor growth” (coef: 0,547) followed. However, the side effects “nausea/
vomiting” and “diarrhea” are considered of relatively equal importance (coef: 0,544 
/ 0,413). The analysis of possible subgroup differences using latent class analysis 
revealed three preference patterns. The adverse event “occurrence of abdominal 
pain” had a significant effect in just one class. cOnclusiOns: The results thus 
provide evidence about how much influence a treatment capacity has on thera-
peutic decision. The preference measurement showed that “overall survival” has 
the strongest influence on the therapeutic decision. The preference analysis also 
made it clear that the participants weight the outcome attributes higher than the 
side effects. Thus it becomes clear that a mono-criterial decision would not fully 
reflect the patient benefits.
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Objectives: To evaluate the difference in quality of life of hormone-sensitive 
(HSPC) and castrate-resistant (CRPC) prostate cancer patients in the US as meas-
ure by EuroQol-5D and FACT-P. MethOds: Data were extracted from the Adelphi 
Real World Prostate Cancer Disease-Specific Programme© (DSP), a cross-sectional 
survey of 137 urologists and oncologists and their prostate cancer patients, con-
ducted in the US between February and May 2014. Physicians completed detailed 
record forms for the next 12 consulting patients receiving prescribed drug therapy 
for prostate cancer. Each patient was invited to complete a questionnaire which 
included the EQ-5D and FACT-P tools. The scores were compared between HSPC 
and CRPC patients using t-tests or Mann-Whitney tests. Results: The physicians 
provided records for 1,330 prostate cancer patients of which 604 were categorized 
as HSPC and 492 as CRPC. Among the HSPC patients, 203 completed the EQ-5D, the 
mean utility index score was 0.84, which was significantly better (p= 0.0004) when 
compared to 0.78 (n= 182) for CRPC patients. Similarly, the quality of life as meas-
ured by FACT-P was generally better among HSPC patients than CRPC patients in 
a number of domains, including physical well-being [21.0 (n= 203) vs 19.6 (n= 187), 
p= 0.0119] and emotional well-being [15.8 (n= 203) vs 14.7 (n= 186), p= 0.0217], but 
not the social well-being [18.6 (n= 206) vs 19.7 (n= 187), p= 0.0382] and there was no 
statistical difference in the FACT-P score [102.1 (n= 198) vs 98.9 (n= 182). In HSPC 
patients, worse QoL was seen with patients with a worse ECOG performance sta-
tus. cOnclusiOns: The development and subsequent progression of prostate 
cancer to CRPC represents a significant additional humanistic burden for patients, 
as indicated by the significant HSPC vs CRPC difference captured by EQ5D. Multiple 
domains particularly physical and emotional may contribute to the deterioration 
of quality of life during disease progression.
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Objectives: To derive EORTC-8D health state utility values from patient-reported 
EORTC QLQ-C30 scores from the ASPIRE trial. ASPIRE is a randomized, open-label, 
phase 3 trial, which evaluated the efficacy and safety of carfilzomib with lenalido-
mide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in 
relapsed multiple myeloma. MethOds: EORTC-8D is a condition-specific preference 
based measure with eight dimensions from EORTC QLQ-C30: Physical functioning, 
role functioning, pain, emotional functioning, social functioning, fatigue and sleep 
disturbance, nausea and constipation and diarrhea. Episodic random utility model 
(ERUM) was used to derive the EORTC-8D health state utility values from EORTC QLQ-
C30 at baseline for the overall ASPIRE trial population and trial arms using the UK 
tariff. Results: Estimated EORTC-8D utility values ranged from 0.291 to 1.0 which 
is congruent with the expected range of health utility values based on a UK tariff. 
The estimated baseline (cycle 1) utility values [mean (SD)] were 0.7834 (0.1289) for 
the overall population (n= 734), 0.7851(0.1266) and 0.7816 (0.1314) for the KRd (n= 370) 
and Rd (n= 364) treatment arms, respectively. cOnclusiOns: The EORTC-8D enables 
QALYs to be directly estimated using the EORTC QLQ-C30 as an alternative to generic 
measures which may not be as sensitive to quality of life changes in cancer. This 
measure will provide appropriate and useful information for cost per QALY analysis.
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Objectives: Health state utility values (HSUVs) are required for cost-effectiveness 
analysis of new medicines. Health-related quality-of-life data collected from the 
widely accepted EQ-5D are often not available and data from other instruments need 
to be mapped using algorithms. The objective of this study was to map HSUVs using 
data from a clinical trial of patients with relapsed/refractory multiple myeloma 
(RRMM). MethOds: Patient-level EORTC QLQ-C30 and EORTC QLQ-MY20 data were 
collected in a clinical trial of RRMM patients (n= 640) and mapped to EQ-5D scores 
using published algorithms. Descriptive summaries of mapped EQ-5D scores were 
estimated overall, and treatment regimen by: health state (pre-progression, progres-
